Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Step-2-It: Feasibility of SMS Technology to Increase Physical Activity (Step-2-It)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04812756
Recruitment Status : Completed
First Posted : March 24, 2021
Last Update Posted : March 24, 2021
Sponsor:
Information provided by (Responsible Party):
University of Illinois College of Medicine Rockford

Brief Summary:

Rural women are more likely to be obese and have a higher risk for chronic disease than their non-rural counterparts. Inadequate physical activity (PA) at least in part contributes to this increased risk. Rural women face personal, social and environmental barriers to PA engagement. Interventions promoting walking among rural women have demonstrated success; however, few of these studies use text messaging to promote PA.

Step-2-It was a pilot study to assess the feasibility, acceptability, and effectiveness of text-messaging combined with a pedometer to promote PA, specifically walking among English-speaking women, aged 40 and older, living in a rural, northwest Illinois county. There were two components to the 13-week, Step-2-It intervention: (i) participants used the pedometer to track and report their steps via text message daily; and (ii) participants received an informational or motivational text message daily. Enrolled participants completed baseline assessments, received pedometers and two types of automated text messages: motivational messages to encourage walking, and accountability messages to report pedometer steps. Participants engaged in 3, 6, 9, and 12-week follow-ups to download pedometer data, and completed post-intervention assessments at 12 weeks.


Condition or disease Intervention/treatment Phase
Health Behavior Behavioral: Step-2-It - text messaging program Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single group prospective pre-post study
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Step-2-It: A Pilot Study to Assess Feasibility of Using SMS Based Mobile Technology to Increase Physical Activity in Adult Rural Women at Risk for Cardiovascular Disease
Actual Study Start Date : August 15, 2014
Actual Primary Completion Date : February 15, 2015
Actual Study Completion Date : June 15, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Health Checkup

Arm Intervention/treatment
Experimental: Texting intervention
This is a single arm study in which all participants received a pedometer and text messages for the 12 week intervention period. Participants received a content message and a message requesting them to report the number of steps from their pedometer daily.
Behavioral: Step-2-It - text messaging program
participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.




Primary Outcome Measures :
  1. Physical Activity levels [ Time Frame: Change from baseline to end of intervention at 12 weeks ]
    mean steps per day measured using pedometer


Secondary Outcome Measures :
  1. Physical Activity Levels [ Time Frame: Change from baseline to end of intervention at 12 weeks ]
    PA measured via self-report using the BRFSS PA tool

  2. Body-weight [ Time Frame: Change from baseline to end of intervention at 12 weeks ]
    Body weight measured using a calibrated scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women
  • Age 40 and older
  • Reside in Stephenson County
  • Own a cell phone with ability to receive and send text messages
  • Unlimited texting plan
  • Able to give informed consent
  • Speak English

Exclusion Criteria:

  • Men
  • Women under 40 years of age
  • Reside outside Stephenson County
  • No cell phone or no texting ability
  • Non-English speaking
  • Unable to provide informed consent
  • Significant health conditions (including pyelonephritis, current treatment for cancer, other severe illness)
  • Active severe asthma
  • Current pneumonia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04812756


Sponsors and Collaborators
University of Illinois College of Medicine Rockford
Investigators
Layout table for investigator information
Principal Investigator: Manorama M Khare, PhD University of Illinois College of Medicine Rockford
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Illinois College of Medicine Rockford
ClinicalTrials.gov Identifier: NCT04812756    
Other Study ID Numbers: 622085-5
First Posted: March 24, 2021    Key Record Dates
Last Update Posted: March 24, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No